Briquilimab

A potent and differentiated KIT inhibitor proven to drive mast cell depletion.

Briquilimab is a humanized, aglycosylated, antibody that directly inhibits the binding of SCF with the KIT receptor leading to blocking of the KIT signaling pathway and mast cell apoptosis. The interaction of SCF with KIT has been well characterized as essential to mast cell survival, and blocking the interaction has been demonstrated to lead directly to mast cell apoptosis via the Bim-mediated pathway. For many immunological and inflammatory diseases, including chronic urticaria and asthma, this removes the underlying source of the inflammatory response.

Briquilimab was designed to block KIT signaling on mast cells while retaining normal antibody clearance characteristics. This allows Jasper to purse an optimal biologic dosing strategy that leads to depletion of mast cells followed by a drug-free interval allowing return of KIT signaling on other cells to minimize any unwanted effects.